Trends in Mortality and Cause-specific Mortality among patients with Psoriasis and Psoriatic Arthritis in Ontario, Canada.

Bookmark this %label%

There is limited information about mortality rates among patients with psoriasis and psoriatic arthritis (PsA) in North America and their change over the past two decades.To compare all-cause and cause-specific […]

» Read more

“Fake news” in dermatology. Results from an observational, cross-sectional study.

Bookmark this %label%

Social networks have become a means for disseminating information on health-related matters.Describe the characteristics and analyze the accuracy of the dermatology content that is most often shared on the most […]

» Read more

Association of Psoriasis with Colorectal Cancer: A Systematic Review and Meta-Analysis.

Bookmark this %label%

The relation between psoriasis and colorectal cancer (CRC) was largely unclear.To investigate the association of psoriasis with CRC.A systematic review and meta-analysis of observational studies that examined the association of […]

» Read more

QuantiFERON TB-gold conversion rate among psoriasis patients under biologics: a 9-year retrospective study.

Bookmark this %label%

Tuberculosis (TB) screening is mandatory for psoriasis biologic treatment. However, evidences regarding TB screening results during biologic treatment are conflicting.The aim of this study is to evaluate the rate of […]

» Read more

Interventions for chronic palmoplantar pustulosis: abridged Cochrane systematic review and GRADE assessments.

Bookmark this %label%

Palmoplantar pustulosis (PPP) is a chronic inflammatory disease in which sterile and relapsing pustules appear on the palms and soles.To assess the effects of interventions for chronic PPP to induce […]

» Read more

Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).

Bookmark this %label%

Data for the effect of metabolic syndrome (MetS) on efficacy and safety of biologic agents for psoriasis treatment are limited.To evaluate long-term tildrakizumab efficacy, drug survival, and safety in patients […]

» Read more

Twice-weekly topical calcipotriene / betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial).

Bookmark this %label%

Topical psoriasis treatment relies on a reactive, rather than long-term proactive, approach to disease relapse.Assess long-term efficacy and safety of proactive psoriasis management with twice-weekly calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) […]

» Read more

Clinical Presentation and Management of Atypical and Recalcitrant Acute Generalized Exanthematous Pustulosis (AGEP).

Bookmark this %label%

Acute generalized exanthematous pustulosis (AGEP) is a severe cutaneous adverse reaction (SCAR) characterized by sterile non-follicular pustules on an erythematous base that form rapidly after drug exposure. AGEP is mediated […]

» Read more

Clinical Presentation and Management of Atypical and Recalcitrant Acute Generalized Exanthematous Pustulosis (AGEP).

Bookmark this %label%

Acute generalized exanthematous pustulosis (AGEP) is a severe cutaneous adverse reaction (SCAR) characterized by sterile non-follicular pustules on an erythematous base that form rapidly after drug exposure. AGEP is mediated […]

» Read more

A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial.

Bookmark this %label%

Significantly more patients with moderate-to-severe plaque psoriasis treated with the interleukin (IL)-17A inhibitor ixekizumab vs. the IL-23p19 inhibitor guselkumab in the IXORA-R head-to-head trial achieved 100% improvement in Psoriasis Area […]

» Read more

Modifiable Lifestyle and Environmental Factors Associated with Onset of Psoriatic Arthritis in Patients with Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.

Bookmark this %label%

Psoriatic arthritis (PsA) is a progressive joint disease associated with psoriasis.To investigate the association of modifiable lifestyle and environmental factors with PsA risk among people with psoriasis.We conducted a systematical […]

» Read more

Reduced Risk of Mortality Associated With Systemic Psoriasis Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A Nested Case-Control Analysis.

Bookmark this %label%

The effects of systemic therapy on mortality risk among patients with psoriasis are not fully understood.To evaluate the impact of systemic treatment on mortality risk in patients enrolled in the […]

» Read more

The association of psoriasis and hypertension: focusing on anti-inflammatory therapies and immunological mechanisms.

Bookmark this %label%

Psoriasis is a chronic skin disease characterized by recurrent inflammation, and is increasingly being recognized as a systemic inflammatory disorder, which is associated with cardiovascular events, metabolic syndrome, diabetes, obesity […]

» Read more

A phase I, randomized, double-blind study to assess the safety, tolerability, and efficacy of the topical RORC2 inverse agonist PF-06763809 in participants with mild-to-moderate plaque psoriasis.

Bookmark this %label%

The transcription factor retinoic acid-related orphan receptor 2 (RORC2/RORγT) mediates interleukin (IL)-17A and IL-17F expression. IL-17A plays a central role in the pathogenesis of several inflammatory disorders, including psoriasis. The […]

» Read more

Research priorities and identification of a health-service delivery model for psoriasis from the UK Psoriasis Priority Setting Partnership.

Bookmark this %label%

Psoriasis impacts the health and psychosocial functioning of patients, conferring a significant economic burden on healthcare systems. There remain unmet needs in psoriasis care, which if addressed by research, could […]

» Read more

Axial psoriatic arthritis: An update for dermatologists.

Bookmark this %label%

Psoriasis is a chronic, immune-mediated, systemic, inflammatory disorder characterized by skin plaques and, often, nail disease and arthritis that contribute to reduced quality of life. Psoriatic arthritis-a heterogeneous, inflammatory, musculoskeletal […]

» Read more

fJoint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.

Bookmark this %label%

Psoriasis is a chronic, inflammatory, multisystem disease which affects up to 3.2% of the U.S population. This guideline addresses important clinical questions that arise in psoriasis management and care and […]

» Read more

Shades of grey: what is paediatric psoriasiform dermatitis and what does it have in common with childhood psoriasis?

Bookmark this %label%

While the majority of children with a chronic itchy rash suffer from atopic dermatitis (AD) and other forms of dermatitis, psoriasis is in the differential diagnosis. Certain patterns such as […]

» Read more

Efficacy of a second IL-17 inhibitor in patients with psoriasis: a systematic review and meta-analysis.

Bookmark this %label%

Multiple biologics for psoriasis exist and interleukin (IL)-17 inhibitors are among those with best efficacy. However, switching treatment is often required at some point and intraclass switch of IL-17 inhibitors […]

» Read more

Long-Term Efficacy of Certolizumab Pegol for the Treatment of Plaque Psoriasis: Three-Year Results from Two Randomised Phase 3 Trials (CIMPASI-1 and CIMPASI-2).

Bookmark this %label%

Certolizumab pegol (CZP) is an Fc-free, PEGylated anti-tumour necrosis factor biologic.Report three-year efficacy, pooled from CIMPASI-1 (NCT02326298) and CIMPASI-2 (NCT02326272) CZP in plaque psoriasis (PSO) phase 3 trials.Adults with moderate […]

» Read more

Secukinumab two weekly versus four weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study.

Bookmark this %label%

Secukinumab is a fully human monoclonal antibody that selectively neutralizes IL-17A and shows long lasting efficacy and safety in plaque psoriasis. More evidence is required to optimize secukinumab dosing according […]

» Read more

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): Results from a phase 3, randomised, open-label, efficacy assessor-blinded clinical trial.

Bookmark this %label%

Patients with plaque psoriasis treated with biologic therapies need more efficacious, safe, and convenient treatments to improve quality of life. Risankizumab and secukinumab inhibit interleukin (IL)-23 and IL-17A, respectively, and […]

» Read more

Pilot study: immunohistochemistry expressions of vitamin D receptor associated with severity of disease in psoriasis patients.

Bookmark this %label%

Psoriasis is a chronic inflammatory skin disorder characterized by keratinocyte hyperproliferation, differentiation abnormalities, and resistance to apoptosis. There are several factors that can affect psoriasis and vitamin D is one […]

» Read more
1 2 3 9